INTRODUCTION
============

Runx2 is a transcription factor that belongs to the Runx family composed of Runx1, Runx2, and Runx3. *Runx2* is expressed in multipotent mesenchymal cells, osteoblast-lineage cells, and chondrocytes ([@ref31]). It is also expressed in the thymus and mammary gland. Although Runx2 is not essential for T cell development, it is required for mammary gland development ([@ref50]; [@ref64]). The transcription of the *Runx2* gene is regulated by two promoters, P1 and P2. Both isoforms transcribed from P1 and P2 promoters are expressed in osteoblast-lineage cells and chondrocytes, but *Runx2* expression in these lineages is regulated by the enhancers, most of which remain to be identified ([@ref10]; [@ref27]). Runx2 forms a heterodimer with Cbfb, thereby acquiring increased DNA binding capacity, and binds the consensus sequence TGPyGGPyPy ([@ref31]).

THE FUNCTIONS OF Runx2 IN CHONDROCYTES
======================================

In skeletal development, Sox9 is required for a mesenchymal condensation, and Sox9, Sox5, and Sox6 are required for *Col2a1* expression and cartilage formation ([@ref36]). In long bone, chondrocytes form the growth plate, which is composed of resting, proliferating, prehypertrophic, hypertrophic, and terminal hypertrophic chondrocyte layers ([Fig. 1](#F1){ref-type="fig"}). Chondrocytes continuously differentiate (maturate) in this order. *Runx2* is expressed in resting and proliferating chondrocytes weakly, and its expression is upregulated in prehypertrophic chondrocytes, mildly down-regulated in hypertrophic chondrocytes, and upregulated again in terminal hypertrophic chondrocytes ([@ref22]). Runx2 is required for the differentiation (maturation) of prehypertrophic chondrocytes to hypertrophic chondrocytes ([@ref10]; [@ref63]; [@ref68]). *Runx2*^--/--^ mice lack hypertrophic chondrocytes in most of the skeleton except the tibia, fibula, radius, and ulna, in which hypertrophic and terminal hypertrophic chondrocytes are observed ([@ref22]; [@ref29]). *Runx3* is also expressed in prehypertrophic chondrocytes, and *Runx3*^--/--^ mice exhibit a mild delay in chondrocyte maturation at the embryonic stage. Double knockout mice of *Runx2* and *Runx3* lack hypertrophic chondrocytes in the entire skeleton ([@ref80]). Thus, Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 plays a major role, whereas Runx3 plays a supplementary role in chondrocyte maturation. Runx2 induces *Ihh* expression in prehypertrophic chondrocytes, and Ihh increases chondrocyte proliferation in the proliferating chondrocyte layers. Therefore, Runx2 also regulates chondrocyte proliferation through the induction of *Ihh* expression ([@ref80]). As Ihh induces Pthlh, which inhibits chondrocyte maturation at least partly through the suppression of Runx2, Runx2-Ihh-Pthlh forms a negative feedback loop for chondrocyte maturation ([@ref23]; [@ref69]) ([Fig. 1](#F1){ref-type="fig"}).

![Regulation of the proliferation and differentiation of chondrocytes by Runx2.\
The growth plate is composed of the resting and proliferating chondrocyte layers, which express Col2a1, prehypertrophic chondrocyte layer, which expresses Ihh and Pth1r, hypertrophic chondrocyte layer, which expresses Col10a1, and terminal hypertrophic chondrocyte layer, which expresses Spp1, Ibsp, Mmp13, and Vegfa. Runx2 expression is upregulated in the prehypertrophic chondrocyte layer and induces their maturation into hypertrophic chondrocytes. Runx3 is also involved in this process. Runx2 induces the expression of Ihh, which induces the proliferation of chondrocytes, and Ihh induces the expression of Pthlh, which inhibits *Runx2* expression and chondrocyte maturation through Pth1r, forming a negative feedback loop. Runx2 also regulates the expression of *Col10a1*, *Spp1*, *Ibsp*, *Mmp13*, and *Vegfa*. Ihh induces *Runx2* expression in the perichondrium for the differentiation of osteoblasts, which form the bone collar and primary spongiosa. Most terminal hypertrophic chondrocytes transdifferentiate into osteoblasts.](molce-43-168-f1){#F1}

Overexpression of *Runx2* in chondrocytes accelerates chondrocyte maturation in whole cartilage, including permanent cartilage, thereby impairing joint formation. Tenascin is expressed in permanent cartilage, but its expression is absent in the cartilaginous skeletons of chondrocyte-specific *Runx2* transgenic mice. In chondrocyte-specific dominant-negative *Runx2* transgenic mice, tenascin is expressed in the whole cartilaginous skeleton ([@ref68]). Thus, Runx2 determines whether chondrocytes become those in transient cartilage like the growth plate or those in permanent cartilage like articular cartilage ([@ref30]). Runx2 induces the expression of Mmp13 and Adamts5, which disrupt the matrix of articular cartilage ([@ref17]; [@ref19]; [@ref25]; [@ref58]; [@ref61]; [@ref65]; [@ref66]; [@ref72]). Furthermore, *Runx2*^+/--^ mice are resistant to osteoarthritis (OA) progression, chondrocyte-specific deletion of *Runx2* decelerates OA progression, and tamoxifen-induced *Runx2* expression in articular cartilage accelerates OA progression in an experimental OA mouse model ([@ref6]; [@ref26]; [@ref37]). In addition to Runx2 expression, the expression of Mmp13, Ihh, and Col10a1, which is regulated by Runx2, is increased in human OA cartilage ([@ref5]). Chondrocyte maturation is an important aspect of OA, and Runx2 plays a key role in the pathogenesis of OA.

FUNCTIONS OF Runx2 IN OSTEOBLASTS
=================================

*Ihh*^--/--^ mice lack osteoblasts in endochondral bones and Runx2 expression is absent in the perichondrium, suggesting that Ihh is required for *Runx2* expression in osteoprogenitors in endochondral bones ([@ref60]). The binding of Ihh to the receptor Ptch relieves the repression of Smo by Ptch, and Smo ultimately regulates Gli ([@ref59]). In Smo conditional knockout mice using *Col2a1* Cre, which directs Cre expression in chondrocytes and perichondrial cells that contain osteoblast progenitors, *Runx2* expression is absent in the perichondrium but is detected in cells outside of the perichondrium ([@ref39]). However, deletion of *Smo* by *Sp7* Cre, which directs Cre expression in preosteoblasts, does not affect osteoblast differentiation ([@ref55]). Thus, the requirement of the activation of hedgehog signaling pathway for Runx2 expression and osteoblast differentiation is restricted to the stage of osteoprogenitors in endochondral bone development ([Fig. 2](#F2){ref-type="fig"}).

![Regulation of the proliferation and differentiation of osteoblast-lineage cells by Runx2.\
Ihh is required for *Runx2* expression, and hedgehog signaling and Runx2 induce the differentiation of multipotent mesenchymal cells into preosteoblasts in endochondral bone. Runx2 activates the hedgehog signaling pathway through the induction of *Ihh*, *Gli1*, and *Ptch1*. Runx2, Sp7, and the canonical Wnt signaling pathway induce the differentiation of preosteoblasts into immature osteoblasts. Runx2 induces *Sp7* expression at the preosteoblast stage, Runx2 activates the Wnt signaling pathway through the induction of *Tcf7* and *Wnt10b* expression, and Sp7 and Tcf7 activate a *Runx2* enhancer. Runx2 and Sp7 induce the differentiation of immature osteoblasts into mature osteoblasts. Runx2 induces the proliferation of multipotent mesenchymal cells, osteoprogenitors, and preosteoblasts through the regulation of Fgf, hedgehog, Wnt, and Pthlh signaling pathway genes. The mutual regulation between Runx2 and the signaling pathways, including hedgehog, Fgf, Wnt, and Pthlh, or Sp7 plays important roles in the proliferation and differentiation of osteoblast-lineage cells and their progenitors.](molce-43-168-f2){#F2}

Conditional *Ctnnb1* knockout mice using *Twist2* Cre, which directs Cre expression in osteo-chondroprogenitors, *Col2a1* Cre or *Prrx1* Cre, which directs Cre expression in osteoprogenitors in calvaria and osteo-chondroprogenitors in limb skeletons, lack osteoblasts, but Runx2 is expressed in the perichondrium ([@ref8]; [@ref18]; [@ref20]; [@ref55]). Thus, activation of the Wnt signaling pathway is essential for osteoblast differentiation, but not for *Runx2* expression in osteoprogenitors ([Fig. 2](#F2){ref-type="fig"}). Sp7 is another transcription factor essential for osteoblast differentiation. *Sp7*^--/--^ mice lack osteoblasts, but Runx2 is expressed in the osteoprogenitors ([@ref45]). *Sp7* is expressed in preosteoblasts and osteoblasts, and Runx2 induces *Sp7* expression ([@ref79]). Therefore, it is an upstream transcription factor of Sp7. In conditional *Ctnnb1* knockout mice and *Sp7*^--/--^ mice, osteoprogenitors differentiate into chondrocytes. Therefore, osteoprogenitors that express *Runx2* retain the ability to differentiate into chondrocytes, and Wnt signaling and Sp7 induce the differentiation of osteoprogenitors into osteoblasts, inhibiting their differentiation into chondrocytes ([Fig. 2](#F2){ref-type="fig"}).

Osteoprogenitors and preosteoblasts weakly express type I collagen, which is a heterotrimeric protein composed of two α1(I) chains and one α2(I) chain encoded by *Col1a1* and *Col1a2*, respectively. Immature osteoblasts upregulate *Col1a1* and *Col1a2* expression, and express *Spp1* and *Ibsp*, and mature osteoblasts express osteocalcin encoded by *Bglap2* and *Bglap* ([@ref2]; [@ref42]). *In vitro* studies demonstrated that Runx2 upregulates the expression of these genes ([@ref9]; [@ref16]). Indeed, *Runx2*^--/--^ mice lack osteoblast-lineage cells expressing these genes ([@ref32]). The expression of *Spp1* and *Bglap2* is reduced, but that of *Col1a1* is increased, in the bone of type II *Runx2*-deficient mice, in which the P1 promoter and exon I of *Runx2* are deleted ([@ref76]). Two groups reported conditional *Runx2* knockout mice using 2.3 kb *Col1a1* Cre, which directs Cre expression in osteoblasts. The deletion of the runt domain in osteoblasts resulted in no bone phenotype, whereas the deletion of exon 8, which creates cryptic Runx2 protein that retains DNA binding capacity but has lower transcriptional activation ability, resulted in reduced bone mass ([@ref1]; [@ref62]). As the cryptic Runx2 protein may interfere with the binding of Runx3, which is also involved in bone formation ([@ref3]), the regulation of bone matrix protein gene expression by Runx2 *in vivo* needs to be investigated further.

REGULATION OF THE PROLIFERATION OF OSTEOBLAST-LINEAGE CELLS BY Runx2
====================================================================

Overexpression of *Runx2* using the *Prrx1* promoter results in craniosynostosis and limb defects ([@ref41]). The severity of limb defects is dependent on the expression level of the transgene. Limbs develop through an epithelial-mesenchymal interaction loop formed by fibroblast growth factors (Fgfs) and Fgf receptors (Fgfrs) ([@ref47]; [@ref77]). Fgf10, which is expressed in the mesenchyme, induces *Fgf4* and *Fgf8* expression in the epithelium through Fgfr2b with high affinity for Fgf10, which is expressed in the epithelium. Fgf4 and Fgf8 induce the proliferation of mesenchymal cells through Fgfr1c and Fgfr2c with high affinity for Fgf4 and Fgf8. In *Runx2*-overexpressing mice, *Fgf4* and *Fgf8* expression in the epithelium is impaired, and apical ectodermal ridge (AER) formation is interrupted. These phenotypes are caused by the upregulated expression of Fgfrs with a high affinity for Fgf10 in the mesenchyme. Runx2 induces the expression of *Fgfr1*, *Fgfr2*, and *Fgfr3* via direct regulation of their promoters ([@ref28]).

*Ctnnb1*^--/--^ mice and *Sp7*^--/--^ mice exhibit similar phenotypes. Both lack osteoblasts, but have abundant osteoprogenitors in the presumptive bone regions ([@ref8]; [@ref18]; [@ref20]; [@ref28]; [@ref45]). Although *Runx2*^--/--^ mice also lack osteoblasts, osteoprogenitors are limited in the presumptive bone regions ([@ref28]; [@ref32]). Osteoprogenitors in *Sp7*^--/--^ mice express Runx2 and are actively proliferating. Of note, tibiae and fibulae in *Sp7*^--/--^ mice are bent due to the accumulation of osteoprogenitors in the perichondrium ([@ref28]). These findings suggest that Runx2 is required for the expansion of osteoprogenitors. Indeed, Runx2 induced the proliferation of osteoprogenitors originating from wild-type and *Sp7*^--/--^ mice, and increased Fgf2-induced proliferation. Fgfr2 and Fgfr3 are involved in proliferation, and Fgfr2 plays a major role because its expression level is much higher than that of *Fgfr3* in calvaria. The amount of osteoprogenitors and their frequency of proliferation in *Sp7*^--/--^*Runx2*^+/--^ mice are half of those in *Sp7*^--/--^ mice, indicating that the proliferation of osteoprogenitors is dependent on the gene dosage of *Runx2*. Thus, Runx2 is required for the proliferation of osteoprogenitors, which is induced via the direct regulation of *Fgfr2* and *Fgfr3* ([@ref28]) ([Fig. 2](#F2){ref-type="fig"}).

However, previous reports demonstrated that Runx2 inhibits the proliferation of osteoblast-lineage cells or mesenchymal stem cells *in vitro* ([@ref13]; [@ref15]; [@ref40]; [@ref52]; [@ref67]). *Runx2*^--/--^ calvarial cells proliferate faster than wild-type calvarial cells *in vitro* ([@ref28]). Microarray analysis revealed that the expression of cell cycle-related genes is different between calvaria tissue and calvaria-derived cells in culture in *Runx2*^--/--^ mice ([@ref28]). Although the reason why *Runx2*^--/--^ calvarial cells acquire high proliferation activity *in vitro* is unclear, Runx2 increases the proliferation of osteoblast progenitors *in vivo* and *in vitro*.

MECHANISM OF THE PROLIFERATION OF MESEN­CHYMAL CELLS AND THEIR COMMITMENT TO OSTEOBLAST LINEAGE CELLS
=====================================================================================================

Calvaria development is a good model to elucidate the mechanism of the differentiation of mesenchymal cells into osteoblasts. *Runx2*^--/--^ mice have no calvarial bone and only a thin layer of mesenchymal cells ([@ref32]). *Runx2*^+/--^ mice develop calvarial bone, but the process is delayed and the sutures are not closed ([@ref54]). Cleidocranial dysplasia, which is characterized by open fontanelle and sutures, dysplasia of clavicles, supernumerary teeth, and short stature, is caused by heterozygous mutation of the *RUNX2* gene ([@ref35]; [@ref44]; [@ref49]). Calvarial bone is formed through intramembranous ossification by osteoblasts, which differentiate from suture mesenchymal cells. Therefore, sutures close through the process of intramembranous ossification, but the posterior frontal suture is an exception. In the posterior frontal suture, mesenchymal condensation occurs at around P7 in mice, the mesenchymal cells differentiate into chondrocytes, the chondrocytes mature, and the cartilage is replaced by bone through endochondral ossification ([@ref4]; [@ref54]; [@ref56]).

In *Runx2*^+/--^ mice, chondrocytes never appear in the posterior frontal suture and the cell density is low in all of the sutures. The suture cells express both Sox9 and Runx2 in wild-type and *Runx2*^+/--^ mice. The expression level of *Sox9* is similar between wild-type and *Runx2*^+/--^ mice. Indeed, the levels of *Runx2* mRNA in suture cells and osteoblasts in *Runx2*^+/--^ mice are approximately half of the respective level in wild-type mice. The expression level of *Runx2* mRNA in suture cells is one-third to half of that in osteoblasts of calvarial bone. The proliferation of suture cells is markedly reduced in *Runx2*^+/--^ mice compared with in wild-type mice. The expression of hedgehog, Fgf, Wnt, and Phhlh signaling pathway genes, including *Gli1*, *Ptch1*, *Ihh*, *Fgfr2*, *Fgfr3*, *Tcf7*, *Wnt10b*, and *Pth1r*, are reduced in the suture of *Runx2*^+/--^ mice compared with in wild-type mice. Moreover, the expression of these genes is directly regulated by Runx2. However, their expression, as well as that of *Sp7*, *Col1a1*, and *Bglap2*, is not reduced in calvarial bone tissue of *Runx2*^+/--^ mice compared with that of wild-type mice. This suggests that more than a half-dosage of *Runx2* is required for the proliferation of suture mesenchymal cells and their commitment into osteoblast-lineage cells, and for the induction of hedgehog, Fgf, Wnt, and Phhlh signaling pathway genes; however this half-dosage of *Runx2* is sufficient for the committed osteoblasts to induce the expression of these signaling pathway genes, *Sp7*, and bone matrix genes. Furthermore, hedgehog agonists, FGF2, Wnt3a, and Pthlh (1-34) increased calvarial bone formation, whereas antagonists reduced the bone formation and proliferation of suture mesenchymal cells. Therefore, Runx2 induces suture mesenchymal cell proliferation and their commitment into osteoblast-lineage cells by increasing the expression of hedgehog, Fgf, Wnt, and Pthlh signaling pathway genes ([@ref54]) ([Fig. 2](#F2){ref-type="fig"}). Among these signaling pathways, the Fgf signaling pathway likely plays the most important role in the proliferation of mesenchymal cells, osteoprogenitors, and preosteoblasts ([@ref28]; [@ref54]).

Ihh is required for *Runx2* expression ([@ref60]). Fgf2 and Fgf18 increase the capacity of Runx2 for transcriptional activation and stabilize Runx2 protein via phosphorylation though the MAPK pathway, and Runx2 is activated through the PI3K-Akt pathway ([@ref12]; [@ref14]; [@ref28]; [@ref51]; [@ref75]). Wnt signaling and Sp7 activate the *Runx2* enhancer ([@ref27]). Furthermore, parathyroid hormone (PTH), which has similar functions to Pthlh, increases *Runx2* mRNA and increased its activity through protein kinase A in an osteosarcoma cell line, and anabolic functions of PTH in bone were induced in Runx2-dependent manner in metatarsal organ culture ([@ref33]). Therefore, there is mutual regulation between Runx2 and these signaling pathways, including hedgehog, Fgf, Wnt, and Pthlh, or Sp7 ([Fig. 2](#F2){ref-type="fig"}).

FUNCTIONS OF Cbfb IN Runx2-DEPENDENT BONE DEVELOPMENT
=====================================================

*Runx1*^--/--^ mice and *Cbfb*^--/--^ mice die at midgestation due to the absence of hematopoiesis in the fetal liver, demonstrating that Cbfb is required for Runx1-dependent hematopoiesis in the fetal liver ([@ref48]; [@ref57]; [@ref70]; [@ref71]). To overcome the lethality due to the lack of hematopoiesis, it was partially rescued, confirming the requirement of Cbfb for skeletal development ([@ref34]; [@ref43]; [@ref78]). To more precisely evaluate the functions of Cbfb in skeletal development, several *Cbfb* conditional knockout mice have been generated using *Twist2* Cre, *Col2a1* Cre, *Sp7* Cre, and *Prrx1* Cre ([@ref7]; [@ref11]; [@ref38]; [@ref53]; [@ref73]; [@ref74]). These conditional knockout mice demonstrated that Cbfb is required for osteoblast differentiation, and chondrocyte proliferation and maturation. Furthermore, these mice revealed that Cbfb plays an important role in the stabilization of Runx2 protein by protecting it from degradation by ubiquitination ([@ref38]; [@ref53]). However, the capacity of Cbfb for protein stabilization differs among Runx family proteins ([@ref53]). The protein levels of Runx1, Runx2, and Runx3 in cartilaginous skeleton in *Cbfb* conditional knockout mice using *Twist2* Cre were 3%, 13%, and 8% of those in control mice, respectively. Those in calvariae were 7%, 55%, and 25%, respectively. Therefore, the degree of protein reduction is Runx1 \> Runx3 \> Runx2 in both the cartilaginous limb skeleton and calvaria. Moreover, the degree of reduction was more marked in cartilaginous limb skeleton than in calvaria. The development of calvaria and clavicle was affected more in *Runx2*^+/--^ mice than in *Cbfb* conditional knockout mice, whereas the development of endochondral bone was affected more in *Cbfb* conditional knockout mice than in *Runx2*^+/--^ mice ([@ref53]). Calvaria and the lateral parts of clavicles are formed through intramembranous ossification ([@ref21]). Therefore, intramembranous ossification is highly dependent on the gene dosage of *Runx2*, and the role of Cbfb is greater in endochondral ossification than in intramembranous ossification ([@ref53]). This is explained by the lower stability of Runx family proteins in endochondral skeletons than in intramembranous skeletons in the absence of *Cbfb*, and by the significant roles of Runx1 and Runx3, which are more dependent on Cbfb than Runx2 for protein stability, in endochondral ossification ([@ref53]). The abundance of proteins that can stabilize Runx proteins other than Cbfb may be different among tissues.

Cbfb has two functional isoforms, Cbfb1 and Cbfb2, which are formed by alternative splicing ([@ref46]). Cbfb1^--/--^ mice exhibit normal skeletal development, whereas Cbfb2^--/--^ mice have impaired intramembranous and endochondral bone development ([@ref24]). Cbfb2 is upregulated in Cbfb1^--/--^ mice, but Cbfb1 is not upregulated in Cbfb2^--/--^ mice, resulting in markedly reduced Cbfb expression in Cbfb2^--/--^ mice, but not in Cbfb1^--/--^ mice. This is observed not only in cartilaginous skeletons and calvariae, but also in the liver, thymus, spleen, and heart. However, Cbfb1 has a greater capacity to induce the differentiation of chondrocytes and osteoblasts than Cbfb2. This is caused by the higher ability of Cbfb1 to increase DNA binding by Runx2. In wild-type mice, the expression level of Cbfb2 is three-times higher than that of Cbfb1 in cartilaginous skeletons, calvariae, liver, thymus, and brain. Thus, splicing of Cbfb1 is strictly regulated, and the more potent Cbfb1 and abundant Cbfb2 maintain Runx2 activity at an appropriate level during bone development ([@ref24]).

CONCLUSION
==========

Hedgehog, Fgf, Wnt, and Pthlh signaling pathways induce *Runx2* expression or activate Runx2. Therefore, the proliferation and differentiation of osteoblast-lineage cells are controlled by the reciprocal regulation of Runx2 and these signaling pathways, but not by their cascade ([Fig. 2](#F2){ref-type="fig"}). Although the modification of Runx2 protein for activation is well studied, the transcriptional regulation of the *Runx2* gene in chondrocytes and osteoblast-lineage cells remains to be clarified. Detailed elucidation of the interactions among Runx2, Sp7, and hedgehog, Wnt, Fgf, and Pthlh signaling pathways will reveal the general framework of bone development.
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